BeiGene, Ltd. (6160.HK)
HKD 105.9
(-1.4%)
HKD 105.9
(-1.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.12 Billion USD | 37.39% |
| 2022 | -1.72 Billion USD | -24.4% |
| 2021 | -1.39 Billion USD | 13.21% |
| 2020 | -1.62 Billion USD | -72.85% |
| 2019 | -941.27 Million USD | -35.99% |
| 2018 | -695.38 Million USD | -617.42% |
| 2017 | -93.69 Million USD | 16.07% |
| 2016 | -115.15 Million USD | -106.29% |
| 2015 | -55.2 Million USD | -318.47% |
| 2014 | -14.2 Million USD | -313.41% |
| 2013 | -3.14 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -83.4 Million USD | 64.67% |
| 2024 Q1 | -236.05 Million USD | 34.42% |
| 2023 Q4 | -359.97 Million USD | -220.1% |
| 2023 Q1 | -351.24 Million USD | 25.02% |
| 2023 Q3 | -112.45 Million USD | 62.06% |
| 2023 Q2 | -296.38 Million USD | 15.62% |
| 2023 FY | - USD | 37.39% |
| 2022 Q4 | -468.43 Million USD | -10.96% |
| 2022 FY | - USD | -24.4% |
| 2022 Q3 | -422.15 Million USD | 3.88% |
| 2022 Q2 | -439.21 Million USD | 0.88% |
| 2022 Q1 | -443.09 Million USD | 22.47% |
| 2021 Q1 | 79.79 Million USD | 116.46% |
| 2021 Q2 | -463.31 Million USD | -680.6% |
| 2021 Q3 | -450.14 Million USD | 2.84% |
| 2021 FY | - USD | 13.21% |
| 2021 Q4 | -571.55 Million USD | -26.97% |
| 2020 FY | - USD | -72.85% |
| 2020 Q2 | -358.68 Million USD | 2.0% |
| 2020 Q3 | -431.79 Million USD | -20.38% |
| 2020 Q4 | -484.72 Million USD | -12.26% |
| 2020 Q1 | -366 Million USD | 5.6% |
| 2019 Q1 | -170.33 Million USD | 39.27% |
| 2019 FY | - USD | -35.99% |
| 2019 Q2 | -85.5 Million USD | 49.81% |
| 2019 Q3 | -308.24 Million USD | -260.52% |
| 2019 Q4 | -387.7 Million USD | -25.78% |
| 2018 FY | - USD | -617.42% |
| 2018 Q4 | -280.47 Million USD | -85.85% |
| 2018 Q3 | -150.91 Million USD | 6.1% |
| 2018 Q2 | -160.71 Million USD | -48.03% |
| 2018 Q1 | -108.56 Million USD | -4.75% |
| 2017 Q2 | -57.48 Million USD | -13.41% |
| 2017 Q1 | -50.68 Million USD | -36.0% |
| 2017 FY | - USD | 16.07% |
| 2017 Q4 | -103.64 Million USD | -189.19% |
| 2017 Q3 | 116.2 Million USD | 302.15% |
| 2016 FY | - USD | -106.29% |
| 2016 Q2 | -23.12 Million USD | -21.17% |
| 2016 Q4 | -37.27 Million USD | -8.21% |
| 2016 Q3 | -34.44 Million USD | -48.91% |
| 2016 Q1 | -19.08 Million USD | 27.63% |
| 2015 Q4 | -26.37 Million USD | -106.77% |
| 2015 FY | - USD | -318.47% |
| 2015 Q1 | -9.39 Million USD | -57.77% |
| 2015 Q2 | -4.93 Million USD | 47.43% |
| 2015 Q3 | -12.75 Million USD | -158.38% |
| 2014 Q2 | -1.39 Million USD | 0.0% |
| 2014 Q3 | -5.27 Million USD | -276.9% |
| 2014 Q1 | -1.39 Million USD | 0.0% |
| 2014 FY | - USD | -313.41% |
| 2014 Q4 | -5.95 Million USD | -12.94% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 1327.679% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 330.088% |